Douglas Logan, MD, recently retired from Velocity, but his presence is as big as ever. Talk to our U.S. PIs about their route into research, or their experience at Velocity, and his name is likely to come up. For Matthew Wenker, MD, that story goes back nearly two decades. When he first stepped into clinical … Read more
For much of her early career, Abbie Youkilis, MD focused on changing healthcare from the outside in. Having begun as a pre-med student at Duke, she pivoted into public policy, earning a master’s degree from Harvard and working in Washington on health policy and aging issues. But over time, she found herself drawn back to … Read more
During this year’s World Vaccine Congress, Velocity Clinical Research will host an exclusive “Dine and Discuss” dinner bringing together a select group of senior leaders from across the vaccine and clinical research ecosystem for an off-the-record conversation with vaccine policy and law expert Richard H. Hughes IV. The event forms part of an ongoing series … Read more
There is a logic to the way William Cromwell, MD speaks about cardiometabolic risk — if this, then that. But you never feel as though it would come at the expense of the person sitting opposite him. Over the past 35 years of specialty practice, research, teaching, and publishing, his emphasis has remained the same. … Read more
Velocity Clinical Research is pleased to announce the appointment of Sarah Smiley, DO, FACP, as its new Chief Physician Officer (CPO), reinforcing the company’s commitment to clinical leadership as it continues to grow its global site network and deepen its therapeutic expertise. Dr. Smiley is a seasoned physician investigator with nearly two decades of experience … Read more
Velocity Principal Investigators Douglas K. Logan, MD, and David Ensz, MD, are authors of a newly published Nature Communications article, “Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.” The Phase 1/2 Moderna trial results “demonstrate the proof of concept that mRNA-1020 and mRNA-1030 elicit similar HA-specific immune responses to [hemagglutinin] HA-only … Read more
Tremendous results! Julio Rosenstock, MD, recently authored and presented results for Lilly’s Phase 3 ACHIEVE-1 trial. The once-daily pill significantly reduced A1C (1.3-1.6%) and led to an average 16-pound weight loss. The results were presented by Dr. Rosenstock at the American Diabetes Association Scientific Sessions and published in The New England Journal of Medicine. “The … Read more
At Velocity Clinical Research, we’re proud to be one of the largest clinical trial patient networks in the world, with access to over one million patients in our database across more than 70 integrated sites. That scale puts us in a unique position to listen, learn, and lead—and it’s why we’re excited to share insights … Read more
VISION has now contributed to more than 10,000 participant randomizations worldwide. Additionally, over $12.6 million in stipends have been paid through the VISION Engage mobile app, which is active in four countries and available in four languages. VISION continues to connect more people to clinical trials, enhance the participant experience, and reduce site burden. Learn … Read more
Velocity’s sites in Dallas, TX, and Staszów, Poland, enrolled patients in Novo Nordisk’s Phase 3 trial assessing semaglutide’s effect on participants with metabolic dysfunction–associated steatohepatitis (MASH). Trial results were published in a recent New England Journal of Medicine article detailing the GLP-1 receptor agonist’s impact on liver fibrosis. The study found that “in patients with … Read more